really difficult to find pricing information for each product mobile version of Hims is hard to read all information about the types of treatments Hims offers is in the middle or bottom of the ...

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Both Hims and Keeps offer viable options for treating hair loss. Choosing between the two could come down to product choice, customer service, and personal preference. Share on Pinterest Find out ...

Hims & Hers (HIMS) stock is sinking 20% today after Eli Lilly (LLY) unveiled significantly cheaper versions of its popular weight-loss drugs today. Additionally, the FDA last week hindered the ...

Hims & Hers Health (HIMS) stock enjoyed a 10% jump in price last week on news that the company plans to continue offering compounded ...

Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer healthcare platform said it couldn’t guarantee it would be able to ...

Hims and Hers plans to stop selling compounded weight loss drugs after an FDA update. Hims and Hers' stock fell over 19% in after-hours trading on Monday. The FDA removed semaglutide injections ...

Online health and wellness company Hims & Hers reported fourth-quarter earnings that beat Wall Street analysts' expectations and gave upbeat guidance for 2025. But shares of the company dropped 19 ...

Telehealth company Hims & Hers (HIMS) saw a major boost in app downloads during February. According to a Top-rated analyst, Craig ...